Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications

Very limited labelled indications have been approved for the newer antimicrobials. Data on the clinical uses, efficacy and safety of dalbavancin are scarce, thus here we sought to describe our clinical experience. 16-month observational prospective study was performed. 19 (86%) were used under off-l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eur J Hosp Pharm
Hauptverfasser: Núñez-Núñez, María, Casas-Hidalgo, Inmaculada, García-Fumero, Ricardo, Vallejo-Rodríguez, Inmaculada, Anguita-Santos, Francisco, Hernández-Quero, José, Cabeza-Barrera, José, Ruiz-Sancho, Andrés
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMJ Publishing Group 2020
Schlagworte:
Short Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447242/
https://ncbi.nlm.nih.gov/pubmed/32839266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-001711
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge